+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury



Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury



American Journal of Cardiology 94(11): 1363-1366



This study evaluated whether pretreatment with statins was associated with a decreased incidence of periprocedural myocardial injury. Periprocedural myocardial injury occurs after percutaneous coronary intervention (PCI) and is associated with adverse outcomes. The pleiotropic properties of statins stabilize plaque and decrease the inflammatory milieu of atherosclerotic lesions. Accordingly, we hypothesized that preprocedural statin therapy would decrease periprocedural myocardial injury. We enrolled 425 patients who underwent successful PCI. The control arm (n = 150) included patients not on statin therapy at the time of PCI, and the statin arm (n = 275) included patients who were taking statin medication before PCI. All patients had serial enzymes measured, including creatine kinase (CK), CK-MB, and troponin I. The incidence of increased levels of CK and CK-MB >3 times normal and the absolute increase in CK and troponin I were compared between groups. The control arm had significantly higher periprocedural levels of CK. In the control group, 6% of patients had CK increases >3 times the upper limit of normal compared with 1.8% in the statin group (p = 0.02). The control arm had a higher frequency of CK-MB increases >3 times the upper limit of normal (7.3% vs 2.2%, p = 0.01). There was a trend toward higher levels of troponin I in the control group (3.21 vs 1.85 ng/ml, p = 0.06). Thus, statin therapy before elective PCI was associated with lower levels of periprocedural CK.

(PDF emailed within 0-6 h: $19.90)

Accession: 012003938

Download citation: RISBibTeXText

PMID: 15566904

DOI: 10.1016/j.amjcard.2004.07.140


Related references

The effect of intravenous vitamin C infusion on periprocedural myocardial injury for patients undergoing elective percutaneous coronary intervention. Canadian Journal of Cardiology 30(1): 96-101, 2014

The Effect of High Dose Cilostazol and Rosuvastatin on Periprocedural Myocardial Injury in Patients with Elective Percutaneous Coronary Intervention. Acta Cardiologica Sinica 31(4): 292-300, 2016

Periprocedural myocardial injury during elective percutaneous coronary intervention: is it important and how can it be prevented?. Heart 96(10): 736-740, 2011

Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. International Journal of Cardiology 168(3): 2494-2497, 2014

The randomized clinical trial of coenzyme Q10 for the prevention of periprocedural myocardial injury following elective percutaneous coronary intervention. Cardiovascular Therapeutics 34(4): 254-260, 2017

Intracoronary ST-segment shift soon after elective percutaneous coronary intervention accurately predicts periprocedural myocardial injury. Circulation 114(18): 1948-1954, 2006

Elective percutaneous coronary intervention: the relationship between preprocedural blood glucose levels and periprocedural myocardial injury. Texas Heart Institute Journal 40(4): 410-417, 2014

Impact of increased admission lipid levels on periprocedural myocardial injury following an elective percutaneous coronary intervention. Coronary Artery Disease 26(4): 333-340, 2016

AS-263 Effect of High-dose Statin Pretreatment of Perip-procedural Myocardial Injury during Elective Percutaneous Coronary Intervention in Real World. American Journal of Cardiology 107(8-Supp-S): 108-109, 2011

Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention. Coronary Artery Disease 26(8): 671-677, 2016

A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention. European Journal of Clinical Pharmacology 71(2): 143-149, 2015

High-dose statin pretreatment decreases periprocedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. Plos One 9(12): E113352, 2015

Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention. Lipids in Health and Disease 17(1): 21, 2018

Relationship Between Preoperative Low-Density Lipoprotein Cholesterol and Periprocedural Myocardial Injury in Patients Following Elective Percutaneous Coronary Intervention in Southern China. Medical Science Monitor 24: 4154-4161, 2018

Elective percutaneous coronary intervention leads to significant changes in serum resistin, leptin, and adiponectin levels regardless of periprocedural myocardial injury: an observational study. Anatolian Journal of Cardiology 16(12): 940-946, 2016